Cancer Cachexia Market Size, Share, By Product (Progestogens, Corticosteroids, Combination Therapies, and Others), Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers), Distributional Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Region - Trends, Analysis and Forecast till 2034

• Cancer Cachexia Market size is projected to reach USD 3.6 billion by 2034.
• In 2024, the market was valued at USD 2.45 billion.
• The market is predicted to grow at a CAGR of 4.3% during the forecast period. 

Cachexia is a complex metabolic syndrome characterized by severe and progressive weight loss, mainly due to the depletion of skeletal muscle mass and adipose tissue. This condition occurs more frequently in patients with advanced cancer, especially of the pancreas, lung, and gastrointestinal tract origins. Cachexia is different from simple starvation or anorexia because it involves a concrete interaction among the tumor, the host's immune system, and diverse metabolic pathways. Increasing prevalence of cancer is expected to boost the market expansion during the forecast period.

Key Takeaways:

• The market is being dominated by the North American region due to the rising incidence of cancer and developed healthcare infrastructure.
• Asia Pacific is predicted to witness fast growth due to the increased healthcare infrastructure.

                             To Know More, Request Free Sample Report

Growing Prevalence of Cancer to Augment Market Expansion

• Increasing cancer incidence around the world, especially in the geriatric population, is the prime driver for the market of cancer cachexia. With more people being diagnosed with this dreaded disease, the demand for effective treatment for cachexia, which is a common complication, has also been on the rise.

Limited Treatment Options to Drive Market Growth

• With limited treatment alternatives, presently administered treatments for cancer cachexia are poorly effective, often related incidentally to prohibitory side effects. In the face of this substantial unmet medical need, research and development towards discovering and developing more effective therapies are gearing growth in the market.

Improved Understanding of Cachexia to Aid Market Growth

• Indeed, the better understanding of cachexia: Advances in research have provided a view of the mechanisms behind cancer cachexia, which is helping develop adequate treatment approaches dealing with the specific causative factor, which is involved in loss of muscle mass and body weight. Subsequently, this provides a roadmap for entering new markets.

Restrains:

High treatment costs May Impede Market Growth

• Developing and manufacturing a novel therapy for cancer cachexia can be very costly, and that will make the treatment expensive. High costs in developing treatment may quickly render access to most patients, particularly those in low- and middle-income countries, hence not promoting market growth.

Opportunities:

New therapeutic interventions to Boost Market Expansion

• The discovery of various new therapeutic interventions to aid in the management of cancer cachexia is still under investigation; these could include target therapy, biologics, and their combinations. The market size is very much dependent on their success rate.

The cancer cachexia market is segmented into product, mechanism of action, distribution channel, and region.

Product Insights:

By product, the market is classified into progestogens, corticosteroids, combination therapies, and others. The market is dominated by the progestogens segment due to its benefits, such as increasing appetite and others.

Mechanism of Action Insights:

Based on mechanism of action, the market is bifurcated into appetite stimulators and weight loss stabilizers. The appetite stimulators segment is expected to hold the largest cancer cachexia market share during the forecast period. The segment’s growth is attributed to the increasing appetite and caloric consumption caused by the appetite stimulators.

Distribution Channel Insights:

On the basis of distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacies segment is dominating the market as they are the most effective access site for delivering drugs to treat cancer cachexia.

Regional Insights:

By region, the market is studied across North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.

• North America: Owing to its rising incidence of cancer, developed healthcare infrastructure, and high R&D moves, North America emerges as a leading cancer cachexia market. It has dominant key pharmaceutical companies in this region supplying cancer cachexia drugs with vigorous health policies.

Asia Pacific: The Asia Pacific market is expected to be the fastest-growing, driven by the rising incidence of cancer, improved healthcare infrastructure, and better access to advanced treatment. Major markets in the region include China and India.

Cancer Cachexia Market Report Scope:

Segmentation:

By Product:

• Progestogens
• Corticosteroids
• Combination Therapies
• Others

By Mechanism of Action:

• Appetite Stimulators
• Weight Loss Stabilizers

By Distributional Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

North America

• U.S.
• Canada

Europe

• Germany
• U.K.
• France
• Russia
• Italy
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

The key players operating in the market are AbbVie Inc., Aeterna Zentaris Inc., Aphios Corporation, and others. These key players are adopting strategies, such as new product launches, partnerships and collaborations, and mergers to maintain competitive edge in the market.

List of Key Players in the Market:

• AbbVie Inc.
• Actimed Therapeutics
• Aeterna Zentaris Inc.
• ANI Pharmaceuticals Inc.
• Aphios Corporation
• Aveo Pharmaceuticals Inc.
• Bristol-Myers Squibb Company
• Helsinn Group
• Hikma Pharmaceuticals PLC
• Merck & Co. Inc.
• Mylan N.V.
• Pfizer Inc.
• TCI Peptide Therapeutics
• Teva Pharmaceutical Industries Ltd.

                     To Access More Companies, Download Free Sample PDF

• In February 2024, Meta Fines, a medicine repositioning business, announced that it had reached a licensing agreement with BMI Korea for its cancer cachexia treatment. According to the agreement, BMI Korea will co-own the global technology transfer rights of ASCA101_CC with Meta Fines. It will have the option to license the product in certain regions, including Korea and Southeast Asia. BMI Korea will pay Meta Fines 2 billion won (USD 1.51 million) up front, followed by 46 billion won in tiered milestone payments.  ASCA101_CC is a pipeline that targets cancer cachexia.
• In February 2024, Pfizer is banking on cancer treatments to help it regain its footing after a challenging year marked by a fast decrease in its Covid business. The pharmaceutical company has been attempting to bolster investor enthusiasm after its stock plunged more than 40% in 2023. Pfizer claims its combined medication pipeline with cancer company Seagen could result in at least eight blockbuster treatments by 2030. With Seagen under its belt, Pfizer believes its medical pipeline will generate at least eight blockbuster drugs by 2030, up from five today. However, the business did not specify which treatments it believes have such potential.

More Related Reports

Head and Neck Cancer Market
HER2-Positive Breast Cancer Market
Small Cell Lung Cancer Market
Lung Cancer Market
E-Pharmacy Market